^
    Back
    Association details:
    Biomarker:IL7R mutation
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pediatric Acute Lymphoblastic Leukemia: Regimen components…Consolidation…For CRLF2+ or CRLF2- with JAK2 fusions, EPOR rearrangement, SH2B3 alterations, IL7R insertions/deletions: cyclophosphamide, cytarabine, 6-MP, vincristine, pegaspargase + ruxolitinib; IT therapy: methotrexate
    Secondary therapy:
    cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase + DR6MP